Advancing CLL and MCL Care: The Impact of BTK Inhibitors in Treatment-Naive Patients and Emerging Therapies

home / insights / advancing-cll-and-mcl-care-the-impact-of-btk-inhibitors-in-treatment-naive-patients-and-emerging

Panelists discuss how emerging Bruton tyrosine kinase (BTK) inhibitors and combination regimens are addressing unmet needs in the treatment of chronic lymphocytic leukemia(CLL) and mantle cell lymphoma (MCL), with a focus on improving outcomes for treatment-naive patients and advancing current therapeutic strategies.

Episodes

AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo